By Colin Kellaher
Century Therapeutics has hired Morgan Conn as chief financial officer of the innovative biotechnology company, effective Oct. 14.
Century on Thursday said Conn, 56 years old, most recently served as chief business officer of biopharmaceutical company Pharvaris.
The Philadelphia company said Conn will receive an annual base salary of $470,000, a $100,000 signing bonus and an annual bonus with a target of 40% of his base pay.
Douglas Carr, Century's senior vice president of finance and operations, has been serving as interim principal financial officer since the resignation of Michael Diem as finance chief earlier this year.
Century also said it has named Chad Cowan chief scientific officer, effective Oct. 1. Cowan has been serving as an executive scientific adviser to Century since the company's April acquisition of Clade Therapeutics, where he was chief executive.
The company added that Hy Levitsky, currently president of research and development, will transition from operational duties to serve as an adviser.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 26, 2024 07:25 ET (11:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.